A retrospective cohort study presented at the American College of Gastroenterology investigated whether GLP-1 receptor agonists reduce the risk of early-onset colorectal cancer (EO-CRC) in patients under 50 years of age.
A retrospective cohort study presented at the American College of Gastroenterology investigated whether GLP-1 receptor agonists reduce the risk of early-onset colorectal cancer (EO-CRC) in patients under 50 years of age.
Research presented at the American College of Gastroenterology found that death from both early- and late-stage tumors among patients 20-44 years old has continued to rise.
Research presented at the American College of Gastroenterology found that death from both early- and late-stage tumors among patients 20-44 years old has continued to rise.
A retrospective cohort study presented at the American College of Gastroenterology investigated whether GLP-1 receptor agonists (GLP-1Ras) reduce the risk of early-onset colorectal cancer (EO-CRC) in patients under 50 years of age.
A retrospective cohort study presented at the American College of Gastroenterology investigated whether GLP-1 receptor agonists (GLP-1Ras) reduce the risk of early-onset colorectal cancer (EO-CRC) in patients under 50 years of age.
Researchers sought to determine if postmenopausal women treated with hormone replacement therapy would be at higher risk of developing irritable bowel syndrome.
Researchers sought to determine if postmenopausal women treated with hormone replacement therapy would be at higher risk of developing irritable bowel syndrome.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.